Press Releases

Press Releases

UNIQUE PHARMACEUTICALS, a 503B current Good Manufacturing Practices (CGMP) Outsourcing Facility, today announced its licensure approval in Florida.  The Florida State Board of Pharmacy review committee approved Unique Pharmaceuticals' license June 10 for distribution of sterile and non-sterile compounded medications.  Unique completed its operational transformation to full CGMP standards in…

Press Releases

Calithera Biosciences, Inc., announced today at the JMP Securities Life Sciences Conference in New York City, the selection of CB-1158 as the clinical candidate for their immuno-oncology program targeting inhibition of arginase, a critical immunosuppressive enzyme secreted by myeloid-derived suppressor cells (MDSCs) in tumors. Calithera anticipates submitting an Investigational New…

Press Releases

BIND Therapeutics, Inc., a clinical-stage nanomedicine company developing targeted and programmable therapeutics called Accurins™, today announced that Andrew Hirsch has been appointed president and chief executive officer of the Company. Mr. Hirsch had been serving in the role on an acting basis since March 2015. Mr. Hirsch has also been…

Press Releases

ObsEva, a Swiss biopharmaceutical company developing a novel generation of drugs addressing serious conditions compromising pregnancy from conception to birth, announced today the recruitment of the first patient in the TERM study, a Phase 2 clinical trial in pregnant women with preterm labor of its lead compound OBE001, an orally…

Press Releases

ScinoPharm Taiwan, Ltd. and Raffles PharmaTech announced today the collaboration to manufacture "Celecoxib," a non-steroidal and anti-inflammatory analgesic active pharmaceutical ingredient (API). By combining the R&D expertise of Raffles and the commercial production capability of ScinoPharm (Changshu) Pharmaceuticals, Ltd., both sides aim to exploit greater business opportunities in the US…

Press Releases

Vanda Pharmaceuticals Inc., a biopharmaceutical company focused on the development and commercialization of products for the treatment of central nervous system disorders, today announced that Jim Kelly, Vanda's Senior Vice President and Chief Financial Officer, will deliver a corporate presentation at the JMP Securities Life Sciences Conference in New York…

Press Releases

Aimmune Therapeutics, Inc., a privately held biopharmaceutical company developing desensitization treatments for food allergies, announced today that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation status to AR101, the company’s lead investigational product, for oral immunotherapy of peanut-allergic children and adolescents 4-17 years of age. Breakthrough…

Press Releases

US Oncology Research, one of the nation's largest networks of integrated, community-based oncology practices dedicated to advancing high-quality treatments through clinical trials, announced today a new collaboration with Cure Forward, a patient activation company. US Oncology Research and Cure Forward will work together to make personalized medicine more accessible and…

Press Releases

Selecta Biosciences, Inc., a clinical stage biotechnology company developing a novel class of targeted antigen-specific immune therapies using synthetic vaccine particles (SVP), today announced a publication in the prestigious journal Science1 describing the use of SVP to create a novel vaccine technology designed to target mucosal tissues. For many chronic…

Press Releases

Eli Lilly and Company announced today that its investigational medicine for prevention of migraine (LY2951742, a CGRP neutralizing antibody) met the primary endpoint in a Phase 2b study in episodic migraine. The randomized, double-blind, placebo-controlled study evaluated the efficacy and safety of four different doses of LY2951742 given in a…